{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:32:03Z","timestamp":1793673123525,"version":"4.5.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2020R1A2C3005357"],"award-info":[{"award-number":["2020R1A2C3005357"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2022R1A4A1018930"],"award-info":[{"award-number":["2022R1A4A1018930"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115840","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:31:54Z","timestamp":1695814314000},"page":"115840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19\/T790M\/C797S) mutation"],"prefix":"10.1016","volume":"261","author":[{"given":"Jiyoung","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Joo","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hoe","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Yun","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Gil","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pargat","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeongwon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2665-9431","authenticated-orcid":false,"given":"In Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115840_bib1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1023\/A:1008209720526","article-title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials","volume":"8","author":"Voldborg","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2023.115840_bib2","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00030.2015","article-title":"Expression and function of the epidermal growth factor receptor in physiology and disease","volume":"96","author":"Chen","year":"2016","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2023.115840_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115840_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1357-2725(99)00015-1","article-title":"EGF receptor","volume":"31","author":"Wells","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115840_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Eastern Cooperative Oncology Group, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115840_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1349-7006.2006.00233.x","article-title":"EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification","volume":"9","author":"Yokoyama","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2023.115840_bib7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/annonc\/mdh257","article-title":"Pharmacological background of EGFR targeting","volume":"15","author":"Castillo","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2023.115840_bib8","first-page":"113","article-title":"Role of receptor tyrosine kinases in lung cancer","volume":"74","author":"Maulik","year":"2003","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115840_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrc1159","volume":"3","author":"Muhsin","year":"2003","journal-title":"Gefitinib, Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115840_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd1612","article-title":"Erlotinib hydrochloride","volume":"4","author":"Dowell","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115840_bib11","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115840_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ccr.2007.06.005","article-title":"Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy","volume":"12","author":"Li","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115840_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.6004\/jnccn.2013.0024","article-title":"Second generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers","volume":"11","author":"Yu","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ejmech.2023.115840_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40265-019-01115-y","article-title":"Dacomitinib in the management of advanced non-small-cell lung cancer","volume":"79","author":"Lau","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115840_bib15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1535-7163.MCT-11-0750","article-title":"The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor, Mol","volume":"11","author":"Kim","year":"2012","journal-title":"Cancer Ther."},{"key":"10.1016\/j.ejmech.2023.115840_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v18i3.877","article-title":"Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer","volume":"18","author":"Hirsh","year":"2011","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2023.115840_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1179\/1973947814Y.0000000189","article-title":"Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials","volume":"27","author":"Qi","year":"2015","journal-title":"J. Chemother."},{"key":"10.1016\/j.ejmech.2023.115840_bib18","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jtho.2015.12.093","article-title":"Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non\u2013small cell lung cancer","volume":"11","author":"Song","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2023.115840_bib19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2023.115840_bib20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1535-7163.MCT-17-1033","article-title":"Pharmacological and structural characterizations of Naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non\u2013small cell lung cancer","volume":"17","author":"Hirano","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115840_bib21","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1111\/1759-7714.13587","article-title":"Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats","volume":"11","author":"Wu","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.ejmech.2023.115840_bib22","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-16-1773","article-title":"Osimertinib for the treatment of metastatic EGFR T970M mutation-positive non\u2013small cell lung cancer","volume":"23","author":"Khozin","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115840_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study","volume":"137","author":"Mehlman","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2023.115840_bib24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115840_bib25","doi-asserted-by":"crossref","first-page":"37393","DOI":"10.18632\/oncotarget.26446","article-title":"EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR","volume":"9","author":"Madic","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115840_bib26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaoncol.2015.1066","article-title":"Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain","volume":"1","author":"Yu","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2023.115840_bib27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1021\/acsmedchemlett.8b00314","article-title":"C797S resistance: the undruggable EGFR mutation in non-small cell lung cancer?","volume":"9","author":"Grabe","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115840_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115840_bib29","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115840_bib30","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1538-7445.AM2019-4451","article-title":"Abstract 4451: evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation","volume":"79","author":"Floch","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115840_bib31","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes osimertinib-resistant EGFR-Del19\/T790M\/C797S mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115840_bib32","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1158\/1538-7445.AM2019-1320","article-title":"Abstract 1320: preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor","volume":"79","author":"Liu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115840_bib33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/acsmedchemlett.8b00373","article-title":"Discovery of JND3229 as a new EGFR C797S mutant inhibitor with in vivo mono drug efficacy","volume":"9","author":"Lu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115840_bib34","first-page":"2713","article-title":"Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle, Bioorg","volume":"25","author":"Patel","year":"2017","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115840_bib35","unstructured":"X. Deng, W. Huang, Z. Wu, Y. Wu, C. Yun, J. Zhang, X. Huang, Egfr Inhibitor and Preparation Method and Use Thereof, WO2021238827."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:59:30Z","timestamp":1759330770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":35,"alternative-id":["S0223523423008073"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115840","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19\/T790M\/C797S) mutation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115840"}}